ClinicalTrials.gg
RecruitingNCT07393074PSYLIVER-PILOTUpdated Apr 29, 2026

PSYLIVER-PILOTE: Involvement of the Autonomic Nervous System in Hepatocellular Carcinoma (HCC)

An interventional study of Measurements of autonomic nervous system (ANS) activity at rest and during sensory stimulation. and Self-administered questionnaires to assess psycho-behavioral traits in Hepato Cellular Carcinoma, Cirrhosis and Autonomic Nervous System, sponsored by Hospices Civils de Lyon. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Fibrosis by Hospices Civils de Lyon — 7 open to participants now, 7 under way, none of them phase 3. Fibrosis · Hospices Civils de Lyon.

Started
2026
with 1 other
No phase
8 of 18
2 open now
Registered
17th of 18
by date

Among the 18 studies in Fibrosis by Hospices Civils de Lyon, this one is one of 2 that started in 2026, is one of 8 with no phase, and was the 17th registered.

Fibrosis

1,272 studies on the registry are indexed under Fibrosis; 278 are open to participants now.

Browse Fibrosis studies →

Open to participants now

7 of the 18 studies in Fibrosis by Hospices Civils de Lyon are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 197 Fibrosis studies recruiting now, 112 (57%) set no upper age limit and 53 (27%) stop at 75 or younger; 15 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Fibrosis by Hospices Civils de Lyon, or all of them as a file.
02

Study summary

Chronic liver diseases affect 1.5 billion people worldwide and can lead to cirrhosis and hepatocellular carcinoma (HCC), which ranks as the third leading cause of cancer-related mortality globally. Despite advances in the treatment of hepatitis B and C, metabolic diseases, and addiction, HCC incidence continues to rise. In France, between 2010 and 2015, the five-year survival rate for liver cancer (90% of which is HCC) was 18% for men and 19% for women. Treatment of HCC is based on the BCLC classification (Barcelona Clinic Liver Cancer), which evaluates both cancer progression and liver function (Child-Pugh classification). Patients at early stages (0 or A) have a survival rate of over 5 years, while those at more advanced stages (C or D) have significantly lower survival rates, highlighting the importance of better early detection tools.

Current screening for HCC in cirrhotic patients involves biannual US-scan. However, ultrasound sensitivity for detecting tumors smaller than 2 cm is around 25%. Therefore, developing personalized strategies to predict and detect early-stage HCC is crucial to improving patient outcomes. Various clinical and biological scores have been developed to assess the risk of developing HCC in cirrhotic patients, but these scores remain imperfect. Molecular heterogeneity in HCC, as revealed by transcriptomic studies, could explain the variability in outcomes and treatment responses. This heterogeneity in occurrence, phenotype, and progression of HCC suggests individual singularities that are not yet well understood.

These individual singularities are likely linked to the autonomic nervous system (ANS), particularly in the central nervous system (CNS), which regulates various physiological processes. The ANS consists of the sympathetic nervous system (SNS), mainly adrenergic, and the parasympathetic nervous system (PNS), mainly cholinergic. These two systems function antagonistically but with different temporal dynamics. A better understanding of the interaction between tumor cells and their environment through the ANS could lead to the identification of new biomarkers to predict HCC development and therapeutic targets.

The role of the ANS in cancer development has been explored in various cancers, including prostate, stomach, pancreatic, breast, and ovarian cancers, where the ANS regulates inflammation and immune responses. In chronic liver diseases, the liver is innervated by both sympathetic and parasympathetic fibers, and this innervation plays a role in regulating metabolism, liver regeneration, and fibrosis progression. Chronic liver disease etiologies, such as alcohol consumption, metabolic syndrome, and viral hepatitis, disrupt the balance between the SNS and PNS, contributing to liver dysfunction. The severity of liver damage is linked to autonomic dysfunction, and heart rate variability, a marker of PNS activity, is correlated with survival in patients with terminal-stage HCC.

Our recent research has shown that patients with HCC exhibit a reconfiguration of the intrahepatic ANS, with a consistent cholinergic orientation at the neuro-hepatic synapse. Patients with parasympathetic orientation (as compared to sympathetic orientation) have more aggressive tumors, shorter survival, and, from a pharmacological perspective, anticholinergics increase sensitivity to targeted HCC therapies. Tumor cells and cytotoxic lymphocytes are most strongly associated with cholinergic receptor enrichment and depletion, respectively.

In this context, the PSYLIVER-PILOTE study builds on these findings by investigating the involvement of the ANS in HCC through non-invasive extra-hepatic measures. The SNS and PNS are connected to brain regions involved in cognitive, emotional, and social information processing, such as the anterior cingulate cortex, insula, ventromedial prefrontal cortex, amygdala, and hypothalamus. These brain areas are involved in cognitive control and emotional processing. Additionally, experimental data from polyvagal theory and neurovisceral integration theory highlight the role of the ANS in regulating cognitive, emotional, and social processes, as well as psycho-behavioral traits. For instance, confronting a person with cognitive tasks and emotional or social information alters the balance of sympathetic and parasympathetic activity. Similar changes are observed in psycho-behavioral disorders like depression, emotional dysregulation, stress, and aggression.

Thus, the PSYLIVER-PILOTE study aims to identify extra-hepatic markers of ANS activity associated with HCC, analyzing both electrophysiological indices (from the peripheral nervous system) and psycho-behavioral indices (from the central nervous system). This project could open new avenues for early HCC detection and the development of personalized treatments

03

Conditions studied

  • Hepato Cellular Carcinoma
  • Cirrhosis
  • Autonomic Nervous System
  • Central Nervous System

Browse trials for

Keywords

  • HCC
  • cirrhosis
  • ANS
  • NRS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Group A:

  • Over 18 years of age
  • Affiliated with a social security system
  • Sufficient command of the French language to hold a conversation and read
  • Signature of an form
  • Compensated cirrhosis classified as A with clinical indication for liver (either for the etiological diagnosis or confirmation of cirrhosis, or for the etiological diagnosis of liver damage)
  • Liver biopsy scheduled as part of routine care for a diagnosis of cirrhosis without HCC

Group B:

  • Over 18 years of age
  • Affiliated with a social security system
  • Sufficient command of the French language to hold a conversation and read
  • Signature of an informed consent form
  • Compensated cirrhosis classified as CHILD-Pugh A with clinical indication for liver biopsy (either for the etiological diagnosis of cirrhosis or its confirmation; or for the etiological diagnosis of liver damage)
  • Liver biopsy scheduled as part of routine care for the diagnosis of suspected HCC (based on standard imaging criteria)

Exclusion criteria

Exclusion Criteria:

  • Personal history of cancer in the broad sense (including HCC prior to inclusion in the study)
  • Pregnant or breastfeeding women
  • Adults subject to legal protection measures (guardianship, curatorship)
  • to trans-parietal liver : clinical or radiological ascites, coagulation disorders, curative anticoagulation that cannot be suspended, dilation of the bile ducts
  • Persons deprived of their liberty by judicial or administrative decision
  • Wearers of electronic implants (pacemakers, implantable cardioverter defibrillators, cochlear implants, brain implants, etc.)
  • Psychotic disorders
  • Degenerative neurological disorders (Parkinson's disease and related disorders, dementia, Korsakoff's syndrome, etc.)
  • Antiarrhythmic treatment:

    • Class Ia: Disopyramide and Quinidine
    • Class Ic: Flecainide and Propafenone
  • Neuroleptic psychotropic treatment affecting the ANS (haloperidol, chlorpromazine, olanzapine, clozapine, quetiapine), tricyclic antidepressants (e.g., amitriptyline, amoxapine, clomipramine, etc.)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Patients with histologically proven cirrhosis based on liver biopsy performed as part of routine car

    * Information gathering: patient history, medical history and current treatments, clinical examination and available paraclinical tests, assessment of alcohol consumption * A dedicated consultation at the Croix Rousse hospital to perform: * Measurements of autonomic nervous system (ANS) activity at rest and during sensory stimulation. * Self-administered questionnaires to assess psycho-behavioral traits * Analysis of nocturnal cardiac activity (at home): electrocardiographic (ECG) recording of heart activity during one night. * A study of the liver biopsy (performed as part of routine care) will be carried out to analyze ANS activity at the intrahepatic level for calculating the NRS score

    Other: Measurements of autonomic nervous system (ANS) activity at rest and during sensory stimulation. · Other: Self-administered questionnaires to assess psycho-behavioral traits · Other: Analysis of nocturnal cardiac activity (at home): electrocardiographic (ECG) recording of heart activity during one night. · Other: Calculation of the NRS score. A study of the liver biopsy will be carried out to analyze ANS activity at the intrahepatic level. · Other: Intervention name 5 * (Limit: 100 characters) Optionnal biocollection

  • Experimental
    Patients with cirrhosis complicated by HCC, histologically confirmed by liver biopsy performed as pa

    * Information gathering: patient history, medical history and current treatments, clinical examination and available paraclinical tests, assessment of alcohol consumption * A dedicated consultation at the Croix Rousse hospital to perform: * Measurements of autonomic nervous system (ANS) activity at rest and during sensory stimulation. * Self-administered questionnaires to assess psycho-behavioral traits * Analysis of nocturnal cardiac activity (at home): electrocardiographic (ECG) recording of heart activity during one night. * A study of the liver biopsy (performed as part of routine care) will be carried out to analyze ANS activity at the intrahepatic level for calculating the NRS score

    Other: Measurements of autonomic nervous system (ANS) activity at rest and during sensory stimulation. · Other: Self-administered questionnaires to assess psycho-behavioral traits · Other: Analysis of nocturnal cardiac activity (at home): electrocardiographic (ECG) recording of heart activity during one night. · Other: Calculation of the NRS score. A study of the liver biopsy will be carried out to analyze ANS activity at the intrahepatic level. · Other: Intervention name 5 * (Limit: 100 characters) Optionnal biocollection

Interventions

  • OtherMeasurements of autonomic nervous system (ANS) activity at rest and during sensory stimulation.

    Participants are informed that they will need to watch the screen, on which images will appear around a central symbol. They must click the mouse button as quickly as possible when they see an "x" sign and do nothing when they see a "+" sign appear in the center of the screen. Sensory stimulation is carried out using OpenSesame software. It is divided into four blocks of seven minutes each, with a break systematically offered to participants between each block. Each block comprises three phases: rest (sitting with hands on knees, palms facing upwards and eyes closed) for two minutes, responding to stimuli according to instructions for three minutes, and a second rest phase for two minutes. In fact, participants are only active for a total of 12 minutes. The blocks are presented in the same order for all participants: Go block, neutral Go/NoGo block, emotional Go/NoGo block, then social Go/NoGo block.

  • OtherSelf-administered questionnaires to assess psycho-behavioral traits

    Participants answer self-questionnaires on tablets by selecting the answer that seems most appropriate to them. They are told that there are no right or wrong answers and that they should answer as honestly as possible based on what they think and feel at that moment. The self-questionnaires are the QA-10 items, the short version of the UPPS-P, the BPAQ-SF, the CERQ, the DEX, the PSS-10, the HAD, and the ISI.

  • OtherAnalysis of nocturnal cardiac activity (at home): electrocardiographic (ECG) recording of heart activity during one night.

    The investigator presents the NeuroCoach test kit to the participant and gives it to them. This kit consists of a recorder, two electrodes, a single-use pouch for nighttime use, a prepaid envelope for returning the equipment, and installation instructions. The investigator explains the installation instructions for the device, which the participant will set up independently at home. The equipment used is CE 60601-1 certified (general requirements for basic safety and essential performance of medical electrical equipment). There is a risk of temporary local skin irritation where the electrodes come into contact with the skin. A prepaid envelope will be given to the patient to return the device.

  • OtherCalculation of the NRS score. A study of the liver biopsy will be carried out to analyze ANS activity at the intrahepatic level.

    Liver biopsy is performed as part of routine care. After pathological analysis as part of routine care, the biopsy sample will be sent to the Unité PaThLiv laboratory (UMR UCBL1 INSERM U1350; PathLiv team) for NRS histological scoring.

  • OtherIntervention name 5 * (Limit: 100 characters) Optionnal biocollection

    Venous blood samples (taken during two visits): for a total volume of 32mL(serum, plasma) for the biobank will be aliquoted and stored in cryotubes. Each sample taken will be labeled with the patient's anonymized code (the patient's first and last names will not appear on the tubes). The tubes will be transported to the laboratory (PaThLiv Unit - UMR UCBL1 INSERM U1350; PathLiv Team).

06

What researchers measure

Primary outcomes

  1. RNA expression values encoding all adrenergic receptors, and all cholinergic receptors or subunits.

    The NRS is based on the RNA expression values of 6 human genes encoding all adrenergic receptors, and 21 genes encoding all cholinergic receptors or subunits. The NRS is defined by the difference between the sum of the expression values of adrenergic receptors on the one hand, and the sum of the expression values of cholinergic receptors on the other hand. Hence, the lower the NRS, the more cholinergic the sample is.

    Time frame: At liver biopsy, within 6 months after inclusion

Secondary outcomes

  1. Identify autistic traits

    A short screening questionnaire (AQ-10 (Autism Spectrum Quotient - 10 items)) designed to identify autistic traits in adults, focusing on social skills, attention switching, communication, and imagination.

    Time frame: During the visit, before the liver biopsy, within a maximum of 6 months after inclusion.

  2. Measure assessing five dimensions of impulsivity

    A self-report measure assessing five dimensions of impulsivity: negative urgency, positive urgency, lack of premeditation, lack of perseverance, and sensation seeking.

    Time frame: During the visit, before the liver biopsy, within a maximum of 6 months after inclusion.

  3. Measure assessing different aspects of aggression

    A questionnaire (BPAQ (Buss-Perry Aggression Questionnaire)) measuring different aspects of aggression, including physical aggression, verbal aggression, anger, and hostility.

    Time frame: During the visit, before the liver biopsy, within a maximum of 6 months after inclusion.

  4. Evaluation of the cognitive strategies individuals

    A self-report instrument (CERQ (Cognitive Emotion Regulation Questionnaire)) that evaluates the cognitive strategies individuals use to regulate their emotions after experiencing stressful or negative events.

    Time frame: During the visit, before the liver biopsy, within a maximum of 6 months after inclusion.

  5. Measure assessing everyday problems related to executive dysfunction

    A measure (DEX (Dysexecutive Questionnaire)) assessing everyday problems related to executive dysfunction, such as difficulties with planning, emotional regulation, inhibition, and self-awareness.

    Time frame: During the visit, before the liver biopsy, within a maximum of 6 months after inclusion.

  6. Screening to detect symptoms of anxiety and depression

    A screening tool (HADS (Hospital Anxiety and Depression Scale)) designed to detect symptoms of anxiety and depression, particularly in medical or clinical settings, while minimizing the influence of physical symptoms.

    Time frame: During the visit, before the liver biopsy, within a maximum of 6 months after inclusion.

  7. Measure of heart rate variability

    A global measure of heart rate variability (SDNN (Standard Deviation of NN intervals)) reflecting overall autonomic nervous system activity.

    Time frame: During the visit, before the liver biopsy, within a maximum of 6 months after inclusion

  8. An index of parasympathetic (vagal) activity

    An index (pNN50 (Percentage of NN intervals differing by more than 50 ms) of parasympathetic (vagal) activity based on short-term heart rate variability.

    Time frame: During the visit, before the liver biopsy, within a maximum of 6 months after inclusion

  9. Measure of HRV reflecting parasympathetic nervous system activity.

    A time-domain (rMSSD (Root Mean Square of Successive Differences)) measure of HRV mainly reflecting parasympathetic nervous system activity.

    Time frame: During the visit, before the liver biopsy, within a maximum of 6 months after inclusion.

  10. Measure of total variance of heart rate variability

    The total (Ptot (Total Power)) variance of heart rate variability across all frequency bands, reflecting overall autonomic regulation.

    Time frame: During the visit, before the liver biopsy, within a maximum of 6 months after inclusion.

  11. An index (HF (High-Frequency)) of the parasympathetic activity

    An index of the parasympathetic activity .

    Time frame: During the visit, before the liver biopsy, within a maximum of 6 months after inclusion.

  12. An index often used to estimate the balance between sympathetic and parasympathetic activity

    An index (LF/HF-HRV Ratio) often used to estimate the balance between sympathetic and parasympathetic activity (with interpretative limitations).

    Time frame: During the visit, before the liver biopsy, within a maximum of 6 months after inclusion.

  13. A measure of cardiac vagal modulation.

    A measure (DC (Deceleration Capacity)) of the heart's ability to slow down, reflecting cardiac vagal modulation.

    Time frame: During the visit, before the liver biopsy, within a maximum of 6 months after inclusion.

  14. Mesure spectrale du pouls cardiaque

    A spectral measure (PIP (Pulse Interval Power)) of pulse interval variability indicating autonomic modulation of heart rate.

    Time frame: During the visit, before the liver biopsy, within a maximum of 6 months after inclusion.

  15. A measure associated with slow regulatory mechanisms of the autonomic nervous system

    A measure (VLFI (Very Low Frequency Index)) associated with slow regulatory mechanisms of the autonomic nervous system, including thermoregulation and hormonal influences.

    Time frame: During the visit, before the liver biopsy, within a maximum of 6 months after inclusion.

  16. A measure of rapid changes in skin conductance

    A measure (EDR (Electrodermal Response)) of rapid changes in skin conductance reflecting phasic sympathetic nervous system activity.

    Time frame: During the visit, before the liver biopsy, within a maximum of 6 months after inclusion.

  17. A tonic measure of skin conductance

    A tonic measure of skin conductance (SCL (Skin Conductance Level)) indicating baseline sympathetic arousal.

    Time frame: During the visit, before the liver biopsy, within a maximum of 6 months after inclusion.

  18. A cardiac measure inversely related to sympathetic activity

    A cardiac measure inversely (PEP (Pre-Ejection Period)) related to sympathetic activity; shorter PEP reflects increased sympathetic drive.

    Time frame: During the visit, before the liver biopsy, within a maximum of 6 months after inclusion.

  19. A frequency-domain measure associated with parasympathetic (vagal) activity and respiratory influences.

    A frequency-domain measure (HF-HRV (High-Frequency Heart Rate Variability)) associated with parasympathetic (vagal) activity and respiratory influences.

    Time frame: During the visit, before the liver biopsy, within a maximum of 6 months after inclusion.

  20. An index representing overall sympathetic nervous system activation

    A composite index (SAI (Sympathetic Activity Index)) representing overall sympathetic nervous system activation.

    Time frame: During the visit, before the liver biopsy, within a maximum of 6 months after inclusion.

  21. An index representing overall parasympathetic (vagal) nervous system activity

    A composite index (PAI (Parasympathetic Activity Index)) representing overall parasympathetic (vagal) nervous system activity.

    Time frame: During the visit, before the liver biopsy, within a maximum of 6 months after inclusion.

  22. An index describing the relative balance between sympathetic and parasympathetic cardiac control

    An index (CAB (Cardiac Autonomic Balance)) describing the relative balance between sympathetic and parasympathetic cardiac control

    Time frame: During the visit, before the liver biopsy, within a maximum of 6 months after inclusion

  23. Measure the contribution of sympathetic activity to cardiac autonomic regulation

    A measure (CSAB (Cardiac Sympathetic Autonomic Balance)) emphasizing the contribution of sympathetic activity to cardiac autonomic regulation.

    Time frame: During the visit, before the liver biopsy, within a maximum of 6 months after inclusion

  24. An indicator of overall effectiveness and flexibility of autonomic control over cardiac function

    An indicator (CAR (Cardiac Autonomic Regulation)) of overall effectiveness and flexibility of autonomic control over cardiac function.

    Time frame: During the visit, before the liver biopsy, within a maximum of 6 months after inclusion

  25. Measure reflecting the efficiency of sympathetic regulation of cardiac activity

    A measure (CSAR (Cardiac Sympathetic Autonomic Regulation)) reflecting the efficiency of sympathetic regulation of cardiac activity

    Time frame: During the visit, before the liver biopsy, within a maximum of 6 months after inclusion

  26. A ratio expressing dominance of sympathetic versus parasympathetic autonomic activity

    A ratio (SAI/PAI Ratio) expressing the relative dominance of sympathetic versus parasympathetic autonomic activity.

    Time frame: During the visit, before the liver biopsy, within a maximum of 6 months after inclusion.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Apr 2028, 24 months after the start.

Of 186 non-industry interventional studies with no phase under Fibrosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 57. This study's planned 24 months is below that.

Counting every sponsor, half of 195 studies reached it within 32 months; a quarter within 18 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2026
First posted
Feb 6, 2026
StartActual
Apr 17, 2026
Primary completionEst.
Apr 17, 2028
CompletionEst.
Apr 17, 2028
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07393074
Responsible party
Sponsor
First posted
Feb 6, 2026
Start date
Apr 17, 2026
Primary completion
Apr 17, 2028 (estimated)
Completion
Apr 17, 2028 (estimated)
Last update
Apr 29, 2026

Study contacts

Dr VILLERET François
Contact
francois.villeret@chu-lyon.fr
+33 4 26 73 27 33

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion